A Phase 3 interventional study of Pramipexole 0.125 mg tablet and Pramipexole 0.5 mg tablet in Idiopathic Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 34 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-02.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 9th largest by enrollment, is one of 5 that started in 2006, is one of 6 in phase 3, and was the 11th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2002; this study’s year is marked. 5 started in 2006.
This study's enrollment of 154 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 154 across the 17 interventional studies. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 5 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
21 studies in Restless Legs Syndrome by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 21 studies in Restless Legs Syndrome by Boehringer Ingelheim, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 7 that started in 2006, is one of 6 in phase 3, and was the 10th registered.
Boehringer Ingelheim’s Restless Legs Syndrome studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 21 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of double blind phase in this trial is to compare the efficacy and safety at the fixed dose of 0.25 mg,0.5 mg and 0.75 mg pramipexole in RLS. The objective of open label phase in this trial is to investigate the long term safety and efficacy of pramipexole in RLS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a diagnosis of restless legs syndrome (RLS) according to the following diagnosis criteria of National institute of health (NIH)/International restless legs syndrome study group (IRLSSG):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pramipexole 0.25 mg given once daily
Drug: Pramipexole 0.125 mg tablet
Pramipexole 0.5 mg given once daily
Drug: Pramipexole 0.5 mg tablet
Pramipexole 0.75 mg given once daily
Drug: Pramipexole 0.125 mg tablet · Drug: Pramipexole 0.5 mg tablet
Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 6 Weeks
The International Restless Legs Syndrome Study Group (IRLSSG) proposes classification of severity based on the total score on the IRLS (0-10, mild; 11-20, moderate; 21-30, severe; 31-40, very severe). A decrease in the score of the IRLS by 10 or more points corresponds to the improvement of severity by one rank and has clinical importance. Therefore, the primary endpoint in the double-blind period was set as a decrease by 10 or more points in the mean change on the total score of the IRLS from the baseline to Visit 5 (last observation day in the double-blind period) at all doses of 0.25 mg, 0.5 mg, and 0.75 mg/day of pramipexole.
Time frame: Week 6 - change from baseline
IRLS Responder
The percentage of patients with 50 % or more reduction of IRLS (The measure means the percentage of high responder on the trial medications)
Time frame: baseline to week 6
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score at 6 Weeks
PSQI developed to evaluate the quality of sleep is a self-recording questionnaire consisting of 18 questions focused on 7 factors such as sleep quality, sleep period time, sleep latency, sleep efficiency, sleep difficulty, use of hypnotics, and hindrance to activities of daily living due to daytime sleepiness. Each score (0-3 points) in the respective factors was added to calculate the total score (0-21 points). Rating scale scored from 0 (best sleep) to 21 (worst sleep).
Time frame: Week 6 - change from baseline
Change From Baseline in Japanese Version of the Epworth Sleepiness Scale (JESS) Total Score at 6 Weeks
ESS is a self-recording scale used to evaluate sleepiness experienced in daily activities and it consists of 8 items focused on specific situations such as reading books and watching television. Each score (0-3 points) to 8 questions was added simply to calculate the total ESS score. A Japanese translation of the ESS (a provisional version provided by the Japanese Respiratory Society) used so far had not been prepared through the international scale development and validation process, but the version prepared through this process was published at the 31st meeting of the Japanese Society of Sleep Research. The questions in JESS had been discussed with the original author of the ESS and their measurement concepts had been confirmed. The JESS is the Japanese version of ESS prepared through the international scale development and validation process. Rating scale scored from 0 (no daytime sleep) to 24 (worst daytime sleep)
Time frame: Week 6 - change from baseline
Clinical Global Impression Global Improvement (CGI-I) Responder
CGI is extensively used for risk-benefit evaluation (efficacy) of drug therapies. The CGI evaluates the severity and improvement in 7 ranks. It also evaluates the therapeutic effect and side effects in 4 ranks, separately. Rating scale from 1 (very much improved) to 7 (very much worse). The percentage of patients who were evaluated as 1(very much improved) or 2(much improved) by the investigator were considered responders.
Time frame: baseline to week 6
Patient Global Impression (PGI) Responder
PGI is used to evaluate a global impression by patients themselves in 7 ranks. Rating scale from 1 (very much better) to 7 (very much worse). The percentage of patients where the patient evaluated himself/herself as 1(very much better) or 2(much better)were considered responders.
Time frame: baseline to week 6
Clinically Significant Abnormalities in Vital Signs (Blood Pressure and Pulse Rate in Both Supine and Standing Positions), ECG, Laboratory Tests - Double Blind Period.
Time frame: baseline to 6 weeks
Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 52 Weeks for Open-Label Period
The International Restless Legs Syndrome Study Group (IRLSSG) proposes classification of severity based on the total score on the IRLS (0-10, mild; 11-20, moderate; 21-30, severe; 31-40, very severe).
Time frame: Week 52 - change from baseline
IRLS Responder for Open-label Period
The percentage of patients with 50 % or more reduction of IRLS (The measure means the percentage of high responder on the trial medications)
Time frame: baseline to week 52
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score at 52 Weeks for Open-Label Period
PSQI developed to evaluate the quality of sleep is a self-recording questionnaire consisting of 18 questions focused on 7 factors such as sleep quality, sleep period time, sleep latency, sleep efficiency, sleep difficulty, use of hypnotics, and hindrance to activities of daily living due to daytime sleepiness. Each score (0-3 points) in the respective factors was added to calculate the total score (0-21 points). Rating scale scored from 0 (best sleep) to 21 (worst sleep).
Time frame: Week 52 - change from baseline
Change From Baseline in Japanese Version of the Epworth Sleepiness Scale (JESS) Total Score at 52 Weeks for Open-Label Period
ESS is a self-recording scale used to evaluate sleepiness experienced in daily activities and it consists of 8 items focused on specific situations such as reading books and watching television. Each score (0-3 points) to 8 questions was added simply to calculate the total ESS score. A Japanese translation of the ESS (a provisional version provided by the Japanese Respiratory Society) used so far had not been prepared through the international scale development and validation process, but the version prepared through this process was published at the 31st meeting of the Japanese Society of Sleep Research. The questions in JESS had been discussed with the original author of the ESS and their measurement concepts had been confirmed. The JESS is the Japanese version of ESS prepared through the international scale development and validation process. Rating scale scored from 0 (no daytime sleep) to 24 (worst daytime sleep)
Time frame: Week 52 - change from baseline
Clinical Global Impression Global Improvement (CGI-I) Responder at 52 Weeks for Open-label Period
CGI is extensively used for risk-benefit evaluation (efficacy) of drug therapies. The CGI evaluates the severity and improvement in 7 ranks. It also evaluates the therapeutic effect and side effects in 4 ranks, separately. Rating scale from 1 (very much improved) to 7 (very much worse). The percentage of patients who were evaluated as 1(very much improved) or 2(much improved) by the investigator were considered responders.
Time frame: baseline to week 52
Patient Global Impression (PGI) Responder at 52 Weeks for Open-Label Period
PGI is used to evaluate a global impression by patients themselves in 7 ranks. Rating scale from 1 (very much better) to 7 (very much worse). The percentage of patients where the patient evaluated himself/herself as 1(very much better) or 2(much better)were considered responders.
Time frame: baseline to week 52
Possible Augmentation in RLS Symptoms at 52 Weeks for Open-Label Period
Possible augmentation defined as persistence of a state in which RLS symptoms begin to occur 2 hours earlier than the usual time zone for 5 days or more a week
Time frame: baseline to week 52
| Milestone | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| Started | 48 | 53 | 53 |
| Completed | 43 | 48 | 50 |
| Not completed | 5 | 5 | 3 |
| Withdrew: Adverse event | 2 | 5 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Investigator's judgement | 2 | 0 | 0 |
The International Restless Legs Syndrome Study Group (IRLSSG) proposes classification of severity based on the total score on the IRLS (0-10, mild; 11-20, moderate; 21-30, severe; 31-40, very severe). A decrease in the score of the IRLS by 10 or more points corresponds to the improvement of severity by one rank and has clinical importance. Therefore, the primary endpoint in the double-blind period was set as a decrease by 10 or more points in the mean change on the total score of the IRLS from the baseline to Visit 5 (last observation day in the double-blind period) at all doses of 0.25 mg, 0.5 mg, and 0.75 mg/day of pramipexole.
| Points on a scale | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 6 Weeks | -12.3 ± 1.1 | -12.5 ± 1.1 | -11.8 ± 1.1 |
The percentage of patients with 50 % or more reduction of IRLS (The measure means the percentage of high responder on the trial medications)
| Percentage of patients | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| IRLS Responder | 60.4 | 58.5 | 49.1 |
PSQI developed to evaluate the quality of sleep is a self-recording questionnaire consisting of 18 questions focused on 7 factors such as sleep quality, sleep period time, sleep latency, sleep efficiency, sleep difficulty, use of hypnotics, and hindrance to activities of daily living due to daytime sleepiness. Each score (0-3 points) in the respective factors was added to calculate the total score (0-21 points). Rating scale scored from 0 (best sleep) to 21 (worst sleep).
| Points on a scale | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score at 6 Weeks | -3.2 ± 0.4 | -3.2 ± 0.4 | -2.5 ± 0.4 |
ESS is a self-recording scale used to evaluate sleepiness experienced in daily activities and it consists of 8 items focused on specific situations such as reading books and watching television. Each score (0-3 points) to 8 questions was added simply to calculate the total ESS score. A Japanese translation of the ESS (a provisional version provided by the Japanese Respiratory Society) used so far had not been prepared through the international scale development and validation process, but the version prepared through this process was published at the 31st meeting of the Japanese Society of Sleep Research. The questions in JESS had been discussed with the original author of the ESS and their measurement concepts had been confirmed. The JESS is the Japanese version of ESS prepared through the international scale development and validation process. Rating scale scored from 0 (no daytime sleep) to 24 (worst daytime sleep)
| Points on a scale | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| Change From Baseline in Japanese Version of the Epworth Sleepiness Scale (JESS) Total Score at 6 Weeks | -2.6 ± 0.6 | -3.0 ± 0.5 | -2.3 ± 0.6 |
CGI is extensively used for risk-benefit evaluation (efficacy) of drug therapies. The CGI evaluates the severity and improvement in 7 ranks. It also evaluates the therapeutic effect and side effects in 4 ranks, separately. Rating scale from 1 (very much improved) to 7 (very much worse). The percentage of patients who were evaluated as 1(very much improved) or 2(much improved) by the investigator were considered responders.
| Percentage of patients | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| Clinical Global Impression Global Improvement (CGI-I) Responder | 77.1 | 75.5 | 69.8 |
PGI is used to evaluate a global impression by patients themselves in 7 ranks. Rating scale from 1 (very much better) to 7 (very much worse). The percentage of patients where the patient evaluated himself/herself as 1(very much better) or 2(much better)were considered responders.
| Percentage of patients | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| Patient Global Impression (PGI) Responder | 72.9 | 79.2 | 67.9 |
| participants | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|
| Blood pressure increased | 0 | 1 | 0 |
| Cardiovascular disorder | 0 | 0 | 1 |
The International Restless Legs Syndrome Study Group (IRLSSG) proposes classification of severity based on the total score on the IRLS (0-10, mild; 11-20, moderate; 21-30, severe; 31-40, very severe).
| Points on a scale | Pramipexole 0.125mg Group | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|---|
| Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 52 Weeks for Open-Label Period | -18.5 ± 5.8 | -17.3 ± 5.8 | -18.3 ± 6.1 | -14.8 ± 8.9 |
The percentage of patients with 50 % or more reduction of IRLS (The measure means the percentage of high responder on the trial medications)
| Percentage of patients | Pramipexole 0.125mg Group | Pramipexole 0.25mg Group | Pramipexole 0.50mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|---|
| IRLS Responder for Open-label Period | 100.0 | 90.0 | 92.0 | 68.0 |
PSQI developed to evaluate the quality of sleep is a self-recording questionnaire consisting of 18 questions focused on 7 factors such as sleep quality, sleep period time, sleep latency, sleep efficiency, sleep difficulty, use of hypnotics, and hindrance to activities of daily living due to daytime sleepiness. Each score (0-3 points) in the respective factors was added to calculate the total score (0-21 points). Rating scale scored from 0 (best sleep) to 21 (worst sleep).
| Points on a scale | Pramipexole 0.125mg Group | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|---|
| Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score at 52 Weeks for Open-Label Period | -4.0 ± 2.4 | -3.3 ± 3.3 | -3.3 ± 3.3 | -2.4 ± 3.8 |
ESS is a self-recording scale used to evaluate sleepiness experienced in daily activities and it consists of 8 items focused on specific situations such as reading books and watching television. Each score (0-3 points) to 8 questions was added simply to calculate the total ESS score. A Japanese translation of the ESS (a provisional version provided by the Japanese Respiratory Society) used so far had not been prepared through the international scale development and validation process, but the version prepared through this process was published at the 31st meeting of the Japanese Society of Sleep Research. The questions in JESS had been discussed with the original author of the ESS and their measurement concepts had been confirmed. The JESS is the Japanese version of ESS prepared through the international scale development and validation process. Rating scale scored from 0 (no daytime sleep) to 24 (worst daytime sleep)
| Points on a scale | Pramipexole 0.125mg Group | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|---|
| Change From Baseline in Japanese Version of the Epworth Sleepiness Scale (JESS) Total Score at 52 Weeks for Open-Label Period | -9.5 ± 2.9 | -3.8 ± 4.3 | -4.4 ± 4.7 | -2.6 ± 5.7 |
CGI is extensively used for risk-benefit evaluation (efficacy) of drug therapies. The CGI evaluates the severity and improvement in 7 ranks. It also evaluates the therapeutic effect and side effects in 4 ranks, separately. Rating scale from 1 (very much improved) to 7 (very much worse). The percentage of patients who were evaluated as 1(very much improved) or 2(much improved) by the investigator were considered responders.
| Percentage of patients | Pramipexole 0.125mg Group | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|---|
| Clinical Global Impression Global Improvement (CGI-I) Responder at 52 Weeks for Open-label Period | 100.0 | 95.0 | 98.0 | 84.0 |
PGI is used to evaluate a global impression by patients themselves in 7 ranks. Rating scale from 1 (very much better) to 7 (very much worse). The percentage of patients where the patient evaluated himself/herself as 1(very much better) or 2(much better)were considered responders.
| Percentage of patients | Pramipexole 0.125mg Group | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|---|
| Patient Global Impression (PGI) Responder at 52 Weeks for Open-Label Period | 100.0 | 97.5 | 94.0 | 80.0 |
Possible augmentation defined as persistence of a state in which RLS symptoms begin to occur 2 hours earlier than the usual time zone for 5 days or more a week
| Percentage of patients | Pramipexole 0.125mg Group | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group |
|---|---|---|---|---|
| Possible Augmentation in RLS Symptoms at 52 Weeks for Open-Label Period | 0.0 | 0.0 | 0.0 | 0.0 |
Collected over From the first dose of trial medication onwards through the observational phase (52 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole 0.25mg (Double-blind) | — | 0/48 (0%) | 32/48 (66.7%) |
| Pramipexole 0.50mg (Double-blind) | — | 2/53 (3.8%) | 42/53 (79.2%) |
| Pramipexole 0.75mg (Double-blind) | — | 0/53 (0%) | 42/53 (79.2%) |
| Pramipexole 0.125mg (Open Label) | — | 1/8 (12.5%) | 5/8 (62.5%) |
| Pramipexole 0.25mg (Open Label) | — | 5/140 (3.6%) | 58/140 (41.4%) |
| Pramipexole 0.50mg (Open Label) | — | 0/97 (0%) | 50/97 (51.5%) |
| Pramipexole 0.75mg (Open Label) | — | 0/41 (0%) | 29/41 (70.7%) |
| Event | Pramipexole 0.25mg (Double-blind) | Pramipexole 0.50mg (Double-blind) | Pramipexole 0.75mg (Double-blind) | Pramipexole 0.125mg (Open Label) | Pramipexole 0.25mg (Open Label) | Pramipexole 0.50mg (Open Label) | Pramipexole 0.75mg (Open Label) |
|---|---|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/48 | 0/53 | 0/53 | 1/8 | 0/140 | 0/97 | 0/41 |
| Gastroenteritis bacterialInfections and infestations | 0/48 | 1/53 | 0/53 | 0/8 | 0/140 | 0/97 | 0/41 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/48 | 1/53 | 0/53 | 0/8 | 0/140 | 0/97 | 0/41 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/48 | 0/53 | 0/53 | 0/8 | 1/140 | 0/97 | 0/41 |
| Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/48 | 0/53 | 0/53 | 0/8 | 1/140 | 0/97 | 0/41 |
| MaculopathyEye disorders | 0/48 | 0/53 | 0/53 | 0/8 | 1/140 | 0/97 | 0/41 |
| Pancreatitis acuteGastrointestinal disorders | 0/48 | 0/53 | 0/53 | 0/8 | 1/140 | 0/97 | 0/41 |
| FallInjury, poisoning and procedural complications | 0/48 | 0/53 | 0/53 | 0/8 | 1/140 | 0/97 | 0/41 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/48 | 0/53 | 0/53 | 0/8 | 1/140 | 0/97 | 0/41 |
| Event | Pramipexole 0.25mg (Double-blind) | Pramipexole 0.50mg (Double-blind) | Pramipexole 0.75mg (Double-blind) | Pramipexole 0.125mg (Open Label) | Pramipexole 0.25mg (Open Label) | Pramipexole 0.50mg (Open Label) | Pramipexole 0.75mg (Open Label) |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/48 | 13/53 | 6/53 | 4/8 | 32/140 | 29/97 | 14/41 |
| NauseaGastrointestinal disorders | 6/48 | 22/53 | 25/53 | 1/8 | 11/140 | 15/97 | 11/41 |
| SomnolenceNervous system disorders | 10/48 | 15/53 | 9/53 | 0/8 | 9/140 | 11/97 | 3/41 |
| HeadacheNervous system disorders | 5/48 | 10/53 | 2/53 | 0/8 | 11/140 | 4/97 | 3/41 |
| ConstipationGastrointestinal disorders | 7/48 | 3/53 | 3/53 | 0/8 | 4/140 | 1/97 | 2/41 |
| GastroenteritisInfections and infestations | 1/48 | 0/53 | 1/53 | 1/8 | 0/140 | 0/97 | 1/41 |
| SinusitisInfections and infestations | 0/48 | 0/53 | 0/53 | 1/8 | 1/140 | 0/97 | 0/41 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/48 | 0/53 | 0/53 | 1/8 | 0/140 | 0/97 | 0/41 |
| DizzinessNervous system disorders | 2/48 | 3/53 | 4/53 | 1/8 | 2/140 | 5/97 | 1/41 |
| DysgeusiaNervous system disorders | 0/48 | 1/53 | 0/53 | 1/8 | 0/140 | 0/97 | 0/41 |
| Age, Continuous(years) | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group | Total |
|---|---|---|---|---|
| Mean | 52.5 ± 13.9 | 52.4 ± 12.9 | 54.3 ± 14.4 | 53.1 ± 13.7 |
| Sex: Female, Male(Participants) | Pramipexole 0.25mg Group | Pramipexole 0.5mg Group | Pramipexole 0.75mg Group | Total |
|---|---|---|---|---|
| Female | 30 | 27 | 32 | 89 |
| Male | 18 | 26 | 21 | 65 |
The record gives a start of Oct 2006 and a primary completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole